N/A
N=401
A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults
HIV
Bottom Line
View on ClinicalTrials.gov: NCT02704208 ↗Enrolled (actual)
401
Serious AEs
0.0%
Results posted
Jun 2023
Primary outcome: Primary: Proportion of Participants With an Undetectable HIV Viral Load — 107; 113 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Thrive With Me Control (Behavioral); Thrive With Me Intervention (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Male
- Sponsor
- University of Minnesota
- Primary completion
- May 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Participants With an Undetectable HIV Viral Load |
107; 113 | — |
Summary
The "Thrive With Me" (TWM) trial is testing the efficacy of a mobile enhanced website aimed at improving Antiretroviral Therapy (ART) adherence for HIV-positive men who have sex with men (MSM). TWM is a technology-delivered peer-to-peer social support intervention with social networking and gaming components. In addition to real-time peer-to-peer support capabilities, the TWM intervention provides participants with Antiretroviral Therapy (ART) adherence self-monitoring tools, medication dose reminders, and HIV-related informational content.
Eligibility Criteria
Inclusion Criteria
- 18+ years of age;
- Male gender;
- Sex with 1+ men in the prior year;
- Diagnosis of HIV and currently prescribed ART;
- Self-reported detectable VL in past 12 months OR self-reported problems with HIV medication adherence;
- Residing in the New York City metropolitan area and availability meet with project staff at each assessment time point; and
- English-speaking (since the intervention will be in English).
- Self-reported recent drug use (the sample will be stratified by recent drug use and non-recent drug use)
Exclusion Criteria
- 17 years of age or younger;
- Not male gender;
- 0 male sex partners in the prior year;
- No diagnosis of HIV and/or not currently prescribed ART;
- No self-reported detectable VL in past 12 months OR self- reported very good/excellent HIV medication adherence;
- Residing outside of the New York City metropolitan area and/or no availability meet with project staff at each assessment time point; and
- Non-English-speaking (since the intervention will be in English).
Data sourced from ClinicalTrials.gov (NCT02704208). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.